We invite abstract submissions for the European CNS metastasis Conference taking place in Zurich on February 12-13, 2026.
Date
12 Feb 2026 -
13 Feb 2026
Time
08.30 - 17.05 Uhr
Type
Hybrid
Location
Universitätsspital Zürich, Schmelzbergstrasse 12, 8091 Zürich
Lecture hall
Grosser Hörsaal OST
Call for Abstracts
We invite abstract submissions for the European CNS metastasis Conference taking place in Zurich on February 12-13, 2026.
The deadline for submissions is 15 January 2026.
Selected abstracts will be presented in oral form or e-posters that will be shared to the registered participants.
Submission via e-mail to emilie.lerhun@usz.ch
Program
Thursday, 12th of February 2026
9.15 a.m.
Welcome Coffee, Registration
9.45 a.m.
Opening Remarks
Matthias Guckenberger (University Hospital Zurich)
Matthias Preusser (MedUni Wien)
Emilie Le Rhun (University Hospital Zurich)
Session 1: Pre-clinical research
Chairs: Anna Berghoff, Tobias Weiss
10.00 a.m.
Neural and vascular influences on brain metastasis
Frank Winkler (Heidelberg, DE)
10.30 a.m.
Biological monitoring of melanoma and response prediction
Mitchell Levesque (Zurich, CH)
11.00 a.m.
Pro-Contra Topic: Animal Models
Pro: Amanda Fitzpatrick (London, UK)
Contra: Andreas Wicki (University Hospital Zurich)
11.10 a.m.
Panel Discussion – Animal Models
11.20 a.m.
Coffee Break
Session 2: Novel Diagnostic Approaches
Chairs: Nathalie Albert, Roland Goldbrunner
11.40 a.m.
Methylation profiling for brain metastases
Andreas von Deimling (Heidelberg, DE)
12.10 p.m.
New MRI approaches for diagnosis and follow-up of CNS metastases
Marion Smits (Erasmus Rotterdam)
12.40 p.m.
Pro-Contra Topic: Screening MRI
Pro: Nicolin Hainc (Zurich, CH)
Contra: Volkmar Müller (Hamburg, DE)
12.50 p.m.
Panel Discussion – Screening MRI
12.40 p.m.
Lunch Break
Session 3: Clinical Trials in Progress
Chairs: Matthias Preusser, Johanna Mangana
1.40 p.m.
Selected Abstract 1
1.50 p.m.
Selected Abstract 2
2.00 p.m.
Panel Discussion
2.10 p.m.
Selected Abstract 3
2.20 p.m.
Selected Abstract 4
2.30 p.m.
Selected Abstract 5
2.40 p.m.
Panel Discussion
Session 4: Surgery
Chairs: Carlo Serra, Michael Weller
2.50 p.m.
Neurosurgical Approaches in CNS Metastases: where do we go?
Roland Goldbrunner (Cologne, DE)
3.20 p.m.
Neurosurgical Trials in CNS Metastases: is it the way to go?
Johny Duerinck (Brussels, BE)
3.50 p.m.
Pro-Contra Topic: LITT
Pro: Rachel Grossmann (Haifa, IS)
Contra: Tomas Kazda (Brno, CZ)
4.00 p.m.
Panel Discussion – LITT
4.10 p.m.
Coffee Break
Session 5: Clinical Trial Highlights
Chairs: Sanjay Popat, Caroline Robert
4.30 p.m.
TUXEDO-3
Presented by PI: Matthias Preusser (Vienna, AT)
4.40 p.m.
Discussant
Volkmar Müller (Hamburg, DE)
4.45 p.m.
Panel Discussion
5.00 p.m.
IT-IO
Presented by PI: Emilie Le Rhun (Zurich, CH)
5.10 p.m.
Discussant
Johanna Mangana (Zurich, CH)
5.15 p.m.
Panel Discussion
5.30 p.m.
Final remarks of the day
Matthias Preusser (Vienna, AT) – Emilie Le Rhun (Zurich, CH)
Friday, 13th of February 2026
Session 6: Translational Research
Chairs: Dieta Brandsma, Mitch Levesque
8.30 a.m.
Next steps for histo-molecular and methylation use
Felix Sahm (Heidelberg, DE)
9.00 a.m.
The EViDENCE-BM story
Berend Snijder (Basel, CH)
9.30 a.m.
Pro-Contra Topic: Liquid Biopsy
Pro: Tobias Weiss (Zurich, CH)
Contra: Giulia Berzero (Milan, IT)
9.40 a.m.
Panel Discussion
9.50 a.m.
Coffee Break
Session 7: Radiotherapy and Radioligand Therapy
Chairs: Lizza Hendricks, Matthias Guckenberger
10.10 a.m.
Re-irradiation: how many targets? what is a target?
Luis Schiappacasse (Lausanne, CH)
10.40 a.m.
RT first or Systemic pharmacotherapy first?
Giuseppe Minniti (Rome, IT)
11.10 a.m.
Can PET help to define the target to irradiate?
Ilinca Pop (Freiburg, DE)
11.40 a.m.
Strategies to develop RLT trials in CNS Metastases
Nathalie Albert (Munich, DE)
12.10 p.m.
Pro-Contra Topic: Radioligand Therapy
Pro: Dr. Nelleke Tolboom (Utrecht, NL)
Contra: Dieta Brandsma (Amsterdam, NL)
12.20 p.m.
Panel Discussion
12.30 p.m.
Lunch Break
Session 8: Patient’s Voices
Chair: Michael Weller
1.10 p.m.
Brain metastases: navigating care and the search for clinical ownership
Helen Bulbeck (Isle of Wight, UK)
Session 9: Trial Design
Chair: Rupert Bartsch
1.30 p.m.
Smart Safety Planning and SAE Management in Clinical Research
Regina Grossmann (Zurich, CH)
1.50 p.m.
New Endpoints in CNS Metastases Trials
Michael Weller (Zurich, CH)
2.10 p.m.
Panel Discussion
2.30 p.m.
Coffee Break
Session 10: Pharmacotherapy Advances
Chairs: Matthias Preusser, Emilie Le Rhun
2.50 p.m.
Systemic Therapy in Breast Cancer BM
Rupert Bartsch (Vienna, AT)
3.10 p.m.
Lung Cancer
Sanjay Popat (London, UK)
3.30 p.m.
Melanoma
Caroline Robert (Paris, FR)
3.50 p.m.
Leptomeningeal Metastases
Roberta Rudà (Turin, IT)
4.10 p.m.
Palliative Care
Caroline Hertler (Zurich, CH)
4.30 p.m.
Pro-Contra Topic: Ex vivo drug testing
Pro: Anna Berghoff (Vienna, AT)
Contra: Lizza Hendrikks (Maastricht, NL)
4.40 p.m.
Panel Discussion – Ex vivo drug testing
4.50 p.m.
Final Remarks
Matthias Preusser – Emilie Le Rhun
Sponsors
"*" indicates required fields
Contact
CCCZ Event Management